Business Wire

CO-SWIMLANE

Share
Swimlane Platform Provides Key Automation Capabilities for EMEA Region

Swimlane , provider of the industry's leading security automation platform, today announced details of its continued growth within Europe, Middle East and Africa (EMEA). In 2020, Swimlane achieved significant year over year growth in EMEA and Q4 2020 was the company’s strongest ever quarter in the region. Swimlane’s average number of users per deal across EMEA also grew by 88% year over year, and the average ARR deal size grew by 55% year over year.

Since first launching operations in the U.K. in 2019, Swimlane’s EMEA operations have grown to include locally based employees, including professional services, product engineers and sales staff. Swimlane currently supports customers across DACH, UKI, Nordics, BeNeLux and META, with plans to expand into Southern Europe in 2021.

“Swimlane is focused on providing positive customer experiences and tangible outcomes by helping customers quickly identify the highest value ways to automate their security operations,” said Toby Van de Grift , EMEA Regional Director, Swimlane. “Swimlane has a unique opportunity to support growing security automation and digital transformation goals for organizations across EMEA, such as reducing the financial burden of achieving GDPR compliance through automation. We look forward to continued growth in this region in 2021, as well as recruiting additional partners with complementary technical capabilities.”

Swimlane is the most extensible security automation platform in the market, built from the ground up to support customer’s most sophisticated and challenging automation goals. With drag-and-drop automation design tools, integrations with hundreds of technologies, and unmatched data visualization capabilities, Swimlane is changing what security teams think is possible. As an organization, Swimlane strives to go above and beyond to partner with their customers to create outcomes that not only have immense return on investment for their business, but provide the underlying innovation security teams need to modernize their security operations.

“Swimlane has really helped us to realise the value and importance of security automation in a modern security operations center (SOC). Swimlane gives time back to analysts, so that they can get on with the real work.” - Matthew Helling , Head of Cyber Security Services at Softcat Plc

By design, Swimlane’s platform is fundamentally different from traditional security orchestration, automation and response (SOAR) solutions. To learn more about the Swimlane platform, please request a demo .

About Swimlane

Swimlane is at the forefront of the growing market of security orchestration, automation and response (SOAR) solutions and was founded to deliver scalable and flexible security solutions to organizations struggling with alert fatigue, vendor proliferation and chronic staffing shortages. Swimlane’s solution helps organizations address all security operations (SecOps) needs, including prioritizing alerts, orchestrating tools and automating the remediation of threats—improving performance across the entire organization. Swimlane is headquartered in Denver, Colo. with operations throughout North America, Central America, Europe, the Middle East and Australia. For more information, visit www.swimlane.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye